Skip to main content
. Author manuscript; available in PMC: 2021 Mar 10.
Published in final edited form as: Ann Oncol. 2020 Feb 20;31(5):590–598. doi: 10.1016/j.annonc.2020.02.008

Table 1.

Clinico-pathologic data, reversion status, and RAD51 staining results

Patient ID Germline mutationa Age at dx (years) Stage at dx Receptor status at dx DNA-damaging tx received (line of MBC tx)c Duration of response (months) Best overall response Reason for stopping tx BRCA reversion status post-DNA- damaging tx RAD51 foci status pre- DNA-damaging tx RAD51 foci status post- DNA-damaging tx Subsequent DNA-damaging tx exposure Best response to subsequent DNA-damaging tx
292 BRCA1 p.E23Vfs*17 44 II ER+/PR+/HER2− Carboplatin (4th line) 9 SD PD No UNK UNK None NA
303 BRCA2 c.e9–1 (splice site, somatic) 43 III ER+/PR+/HER2− Cisplatin (5th line) 15 CR PD No Absent Absent None NA
318 BRCA2 p.E1493fs*10 51 I ER+/PR+/HER2− Olaparib (5th line) 11 SD PD Yes, definite Absent Present Carboplatin Intrinsic resistance
339 BRCA2 p.L1908fs*2 30 III ER+/PR+/HER2− Carboplatin (6th line) 6 UNK PD Yes, definite Absent Present None NA
349 BRCA1 p.S454* 29 I ER+/PR+/HER2− Olaparib (4th line) 11 PaR PD Yes, definite Absent Present None NA
359 BRCA1 p.T1677fs*2 53 II ER+/PR−/HER2− Olaparib (2nd line) 4 SD PD No Absent Present Carboplatin Intrinsic resistance
510 BRCA2 p.S1720fs*7 58 III ER+/PR+/HER2− Carboplatin ± veliparibb (6th line) 9 PaR PD Yes, putative Absent Present None NA
565 BRCA1 p.E23Vfs*16 42 II ER−/PR−/ HER2− Veliparib (2nd line) 20 PaR PD No Absent Present Carboplatin and olaparib (separate regimens) Intrinsic resistance to both

Anatomic stage is indicated. Best overall response was determined by RECIST (if patient on a clinical trial) or chart review by a breast medical oncologist (if patient not on a clinical trial). Intrinsic resistance is defined as progressive disease at first restaging or clinical progression before first restaging.

CR, complete response; dx, diagnosis; ER, estrogen receptor; fs, frameshift; MBC, metastatic breast cancer; NA, not applicable; ns, nonsense mutation; PD, progressive disease; PaR, partial response; PR, progesterone receptor; SD, stable disease; tx, treatment; UNK, unknown.

a

One patient (patient 303) had a somatic mutation in BRCA2.

b

This patient underwent blinded randomization to veliparib or placebo on a clinical trial.

c

Timelines indicating all treatments received by all patients, with to-scale durations, are shown in Figure 1, supplementary Figures S1 and S2, available at Annals of Oncology online, and Figure 3. Only DNA-damaging treatment associated with acquired resistance is indicated in the table (and with red arrows in treatment timelines). No patients received platinum or poly(adenosine diphosphate-ribose) polymerase inhibitors for non-metastatic disease.